Monograph
C10AB04 - Gemfibrozil |
Propably not porphyrinogenic |
PNP |
Rationale
Substrate of CYP 3A4. No data pointing to CYP-inducing properties. One reference: use with care. Occasional observations of non-porphyrinogenicity.
Chemical description
Fibric acid derivative used (1200 mg/d) in hyperlipidemia. Longacting. Metabolized by CYP 3A4; inhibitor of CYPs 1A2 (weak), 2C19, 2C8, 2C9. No data point to CYP-induction. Thunell, patient report (n=2): tolerated. South African list: use with care
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Gemfibrozil · Gemfibrozil Auro 600 mg, filmomhulde tabletten · Lopid · Lopid 300 mg, harde capsules · Lopid 450 mg, filmomhulde tabletten · Lopid 600, filmomhulde tabletten 600 mg · Lopid 900, filmomhulde tabletten 900 mgUnited Kingdom
Gemfibrozil · Gemfibrozil 300mg capsules · Gemfibrozil 600mg tablets · Lopid · Lopid 300mg capsules · Lopid 600mg tabletsDenmark
LopidNorway
LopidIceland
Lopid
© NAPOS 2024